Brazil bans PHD of Sao Paulo:
This article was originally published in Clinica
Executive Summary
The Brazilian healthcare surveillance agency, ANVISA, has effectively banned the Sao Paulo-based hospital and diagnostics supplies company PHD Produtos Hospitalares e Diagnosticos Ltda, following last week's market withdrawal of all its products. The measure was adopted because of a number of irregularities reported by the S-o Paulo healthcare vigilance centre, namely that the company did not have a products register and was found to have "forged the use-by dates of its products, by relabelling them", says ANVISA. PHD specialised in contrast agents and other products used in radiography and in computed tomography imaging. Distributors or retail outlets that fail to observe the ban risk a fine of up to R$1.5 million (US$611,000) and a withdrawal of their trading licence.